Full metadata record
DC FieldValueLanguage
dc.contributor.author劉典謨en_US
dc.contributor.authorLiu Dean-Moen_US
dc.date.accessioned2014-12-13T10:42:33Z-
dc.date.available2014-12-13T10:42:33Z-
dc.date.issued2011en_US
dc.identifier.govdocNSC100-2622-M009-002-CC3zh_TW
dc.identifier.urihttp://hdl.handle.net/11536/99235-
dc.identifier.urihttps://www.grb.gov.tw/search/planDetail?id=2314743&docId=362098en_US
dc.description.abstract眼科用藥一般以口服或是眼藥水為主。考量到口服會因人體代謝消耗,而眼藥水 則只有1%到7%的劑量可被眼睛所吸收;因此,本實驗室計畫發展出一種醫用型 隱形眼鏡,除了市面上所要求的高保水性,並具有特殊醫療效果,這也是本研究 計畫的主要重點。利用本實驗室研發出的奈米藥物載體與隱形眼鏡材料silicone hydrogel,製成複合性水膠材料。本實驗室在近年已成功研發出具有生物相容性 之雙性幾丁聚醣(CHC) , 同時加以改質成新的無機- 有機雙性混成分子 (NSC-98-2113-M-009-004),本身同時具有疏水端及親水端,可以將藥物(疏水或 親水)包覆在此結構內部。雙性混成分子可透過自組裝形成奈米顆粒或是中空的 奈米微胞,也可控制其尺寸和疏水程度。利用此雙性混成分子在初步保水性測試, 已可與市面上販售高保水性隱形眼鏡相媲美;而在藥物釋放初期研究(製作成複 合性水膠材料), 顯示可控制的藥物釋放行為, 突顯本計畫之高度可行性。本研 究計畫將深入探討此複合材料的化學、物理、生醫特性。zh_TW
dc.description.abstractOphthalmic solutions are generally administrated via oral or eye drops. In terms of oral, drugs were largely consumed by metabolism, resulting in poor therapeutic efficacy. In terms of eye drops, only 1% to 7% of the dose delivered from eye drop is absorbed by the eye. Therefore, it is technically and industrially important if a contact lens capable of eluting therapeutic agents in a wide variety of manners to meet clinical demands, which renders not only high water uptake, but also imparts diverse therapeutic ability. Combining a novel drug nanocarrier developed recently in this lab, namely amphiphilic hybrid chitosan (CHC), and commercial available silicone contact lens material, giving a composite material, we intend in this proposal to employ the CHC as drug carrier to form a drug-eluting contact lens, a topic that has been raised a huge attention in medical device worldwide in recent decade, but seems very lean and little developed in Taiwan. The CHC hybrid macromolecule has been confirmed capable of self-assembling to hollow nanocapsules with controllable size and hydrophobicity (NSC-98-2113-M-009-004). In our early evaluation, this hybrid molecule appears to show excellent compatibility to the silicone hydrogels (provided from cooperative partner of this proposal) and it also demonstrated a high feasibility of drug elution. On these bases, we believe an in-depth understanding the chemical, physical, and biomedical fundamentals of this system is critically needed and urgent, which is aimed to trigger the development of medical-grade contact lenses.en_US
dc.description.sponsorship行政院國家科學委員會zh_TW
dc.language.isozh_TWen_US
dc.subject雙性幾丁聚醣複合物zh_TW
dc.subject自組裝zh_TW
dc.subject藥物釋放zh_TW
dc.subject矽水膠zh_TW
dc.subject奈米載體zh_TW
dc.subject藥物釋放zh_TW
dc.subjectAmphiphlic hybrid chitosan (CHC)en_US
dc.subjectself-assemblyen_US
dc.subjectcontrolled drug deliveryen_US
dc.subjectsilicone hydrogelen_US
dc.subjectnanocapsuleen_US
dc.title雙性聚多醣-矽膠核-殼奈米膠囊在帶藥型矽水膠隱形眼鏡之研究開發zh_TW
dc.titleSynthesis and Development of Silicone-Based Drug-Eluting Contact Lens Using Polysaccharide-Silicone Core-Shell Nanocapsules with Combined Functionsen_US
dc.typePlanen_US
dc.contributor.department國立交通大學材料科學與工程學系(所)zh_TW
Appears in Collections:Research Plans